Cantuzumab mertansine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Cantuzumab mertansine
Mertansine mab structure.svg
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Clinical data
ATC code
  • none
CAS Number
  • none
 ☒N☑Y (what is this?)  (verify)

Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2] It was developed by ImmunoGen.


After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.[3]

Clinical trials[edit]

Three phase I clinical studies had reported results by 2003.[4] By 2005, clinical development had been suspended.[5]

See also[edit]


  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association. Archived 2011-06-04 at the Wayback Machine
  2. ^ Rodon, J; Garrison, M; Hammond, LA; de Bono, J; Smith, L; Forero, L; Hao, D; Takimoto, C; Lambert, JM; Pandite, L; Howard, M; Xie, H; Tolcher, AW (2008). "Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study". Cancer Chemother Pharmacol. 62: 911–9. doi:10.1007/s00280-007-0672-8. PMID 18301896.
  3. ^ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
  4. ^
  5. ^